Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap443.18M
Enterprise Value488.45M
MYGN
(NASDAQ)Myriad Genetics, Inc.
$4.75-- (--)
Loading... - Market loading
Myriad Genetics (MYGN) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)0.52
Forward Price/Sales0.53
Price/Book (mrq)1.16
Price/Tangible Book (mrq)2.63
Price/OCF (ttm)237.92
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue0.59
EV/Earnings-1.33
EV/EBITDA-1.22
EV/EBIT-1.17
EV/FCF-24.92
Stock Price
Current price, 52-week range, and moving averages
Current Price$4.75
1-Day Change2.00%
52-Week High$8.97
52-Week Low$3.76
52-Week Change-48.08%
YTD Change-25.24%
1-Year Change-47.84%
50-Day MA$4.95
200-Day MA$6.09
Avg Volume (30 day)1.15M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding93.30M
Book Value per Share$3.94
Net Cash per Share$1.53
FCF per Share$-0.21
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$6.00
Target Upside/Downside26.32%
Analyst ConsensusHold
Analyst Count2
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin69.93%
EBITDA Margin (ttm)-48.39%
EBIT Margin (ttm)-50.76%
Operating Margin (ttm)6.69%
Pretax Margin (ttm)-47.92%
Profit Margin (ttm)-44.38%
FCF Margin (ttm)-2.38%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-99.43%
Return on Assets (ttm)-51.78%
Return on Invested Capital (ttm)-77.21%
Return on Capital Employed (ttm)-73.06%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue824.50M
Gross Profit576.60M
Operating Income55.20M
Pretax Income-395.10M
Net Income-365.90M
EBITDA-399.00M
EBIT-418.50M
Diluted EPS$-3.92
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow1.80M
Capital Expenditures21.40M
Free Cash Flow-19.60M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-1.56%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)706.60M
Cash & Securities (mrq)149.60M
Net Cash (mrq)142.70M
Net Cash per Share$1.53
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)209.80M
Working Capital (mrq)198.80M
Total Equity (mrq)368.00M
Book Value per Share$3.94
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)2.49
Quick Ratio (mrq)2.26
Debt/Equity (mrq)0.57
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Ex-Dividend DateJul 1, 2009
Pay DateJul 1, 2009
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-85.44%
FCF Yield-4.58%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-1.92
Piotroski F-Score5/9
Frequently Asked Questions About Myriad Genetics Statistics
What are the key financial metrics for MYGN?
Myriad Genetics, Inc. (MYGN) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is MYGN's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Myriad Genetics is overvalued or undervalued.
How do I read MYGN's profitability ratios?
Myriad Genetics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do MYGN's debt ratios indicate?
The financial health section shows Myriad Genetics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is MYGN's dividend analysis?
The dividend section covers Myriad Genetics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.